Diabetic Neuropathic Pain: Which Treatments Work? medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
The addition of the oral, selective RARα agonist tamibarotene to venetoclax and azacitidine produced higher responses rates compared with venetoclax and azacitidine alone in response-evaluable patients with newly diagnosed, RARA-overexpressed acute myeloid leukemia.
Syros Pharmaceuticals (SYRS) Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Syros Pharmaceuticals (SYRS) announced Wednesday positive initial data from its ongoing SELECT-AML-1 Phase 2 trial evaluating tamibarotene, in combination with venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia or AML and RARA gene overexpression.